More info
Assay Range | 31.2-2,000 pg/mL |
Sensitivity | 10.0 pg/mL |
Specificity | No cross-reaction with other related substances detected |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample Volume | 100 µL final volume, dilution factor varies on samples |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Human LOX-1 standard: 2 vials
2. One 96-well plate coated with Human LOX-1 Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 130 µL, dilution 1:100
5. Streptavidin-HRP: 130 µL, dilution 1:100
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. TMB developing agent: 10 mL x1
9. Stop solution: 10 mL x1
10. Washing solution (20x): 25 mL x1
Background
Lectin like oxidized low density lipoprotein receptor-1 (LOX1), also known as oxidized low density lipoprotein receptor 1 (OLR1), is a type II transmembrane receptor belonging to the C type lectin family. The human LOX1 is synthesized as a 273 amino acid (aa) protein with a short N-terminal intracellular domain, a transmembrane domain, an extracellular stalk/neck region followed by a C type lectin like domain which is required for ligand recognition. LOX1 functions as the scavenger receptor to mediate the internalization of multiple structurally unrelated macromolecules including oxidized LDL, advanced glycation end products (AGE), activated platelets, bacteria, apoptotic or aged cells, and heat shock proteins. Expression of LOX 1 has been observed on activated endothelial cells, vascular smooth muscle cells, macrophages, intestinal cells and dendritic cells, and this expression is induced by proinflammatory or proatherogenic stimuli, as well as by oxidized LDL and hemodynamic or oxidative stress. Human LOX1 exists as covalent homodimers and noncovalent linked oligomers. Cell surface LOX1 can also be cleaved to release the soluble LOX1 extracellular domain. LOX1 mediated oxidized LDL internalization induces oxidative stress, activates NFκB, and upregulates the expression of monocyte chemoattractant protein1 and matrix metalloproteases. Oxidized LDL contributes a lot to the pathogenesis of atherosclerosis and endothelial dysfunction. Blockade of LOX1 may be a suitable target for the therapeutic intervention of atherosclerosis.